Table 2:
Summary of papers positive subgroup effect
| First Author | Sample Size | Average Age (Intervention) | Average Age (Comparator) | Intervention | Primary Outcome | Subgroup | P-value |
|---|---|---|---|---|---|---|---|
| Igonin | 62 | 52 | 50 | C1-esterase inhibitor | 28-day mortality, systemic inflammatory response syndrome criteria (1992 definition) | >65, <65 | >65=0.05 <65=0.09 |
| Lamontagne | 118 | 63 | 66 | High (75–80 mmHg) vs low MAP (60–65mmHg) target | Feasibility outcome: between-group difference in MAP during vasopressor therapy | <75, ≥75 | 0.015 |
| Legriel | 268 | 57 | 57 | Hypothermia (32 to 34°C for 24 hours) | Good functional outcome at 90 days, defined as a Glasgow Outcome Scale (GOS) score of 5 | </=65, >65 | 0.02 |
| Lemkes | 538 | 65.7 | 64.9 | Immediate Angiography | Survival at 90 days | <70, ≥70 | 0.007 |
| Mazer | 5243 | 72 | 72 | Restrictive (<7.5 g/dL) vs liberal (<9.5 g/dL intraoperatively or in the ICU postoperatively OR <8.5 g/dL if on non-ICU ward) red cell transfusion protocol | Death from any cause, myocardial infarction, stroke, or new onset renal failure with dialysis occurring within 28d of surgery | 2017 study: <75, ≥75 | 0.004 |
| Death from any cause, myocardial infarction, stroke, or new onset renal failure with dialysis occurring within 6 months of surgery. | 2018 study: <45, 45–54, 55–64, 65–74, 75–84, ≥85 | ||||||
| Vincent | 309 | 62.9 | 61.6 | Talactoferrin | 28-day mortality | </=65, >65 | 0.04 |